Biontech and crescendo biologics announce global collaboration to develop multi-specific precision immunotherapies

Mainz, germany and cambridge, uk, january 10, 2022 – biontech se (nasdaq: bntx, “biontech”) and crescendo biologics ltd (“crescendo”), a clinical stage immuno-oncology company developing novel, targeted t cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. the initial term of the discovery collaboration is three years.
BNTX Ratings Summary
BNTX Quant Ranking